You are here: Home: Audio Program Guide: LCU 3 | 2006 Audio: LCU 3 | 2006

 
   
  To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
 
Mark A Socinski, MD
Associate Professor of Medicine
Multidisciplinary Thoracic Oncology Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina
  
  Click here to download entire case discussion  
Track 1 Introduction
Track 2 Clinical trial experience with nanoparticle albumin-bound (nab) paclitaxel in lung cancer
Track 3 Potential clinical advantages of nab paclitaxel
Track 4 Trials of nab paclitaxel in the adjuvant setting
Track 5 Nab paclitaxel in combination with radiation therapy for patients with Stage III disease
Track 6 Clinical research with nab paclitaxel in patients with lung cancer
Track 7 Nab paclitaxel for patients pretreated with a taxane
Track 8 Use of bevacizumab in the treatment of lung cancer
Track 9 Studies combining nab paclitaxel with bevacizumab
Track 10 Selection of chemotherapeutic agents to combine with bevacizumab
Track 11 Contraindications to the use of bevacizumab
Track 12 Potential mechanisms of hemoptysis with bevacizumab
Track 13 Hemoptysis associated with sunitinib in patients with lung cancer
Track 14 Efficacy, tolerability and dosing of the dual VEGF/EGFR tyrosine kinase inhibitor ZD6474
Track 15 Phase II trial evaluating docetaxel combined with two different doses of ZD6474 as second-line therapy
Track 16 Potential benefit of combining erlotinib with bevacizumab
Track 17 Selection of patients for treatment with erlotinib
Track 18 Management of erlotinib-associated rash

 
Nasser H Hanna, MD
Assistant Professor
Department of Medicine
Division of Hematology/Oncology
School of Medicine
Indiana University Medical Center
Indianapolis, Indiana
  
  Click here to download entire case discussion  
Track 1 Introduction
Track 2 Clinical research evaluating erlotinib combined with bevacizumab for patients with performance status II
Track 3 Continuation of erlotinib after tumor response and subsequent disease progression
Track 4 Benefit of erlotinib in combination with bevacizumab as second-line therapy
Track 5 Predictors of response to EGFR inhibitors
Track 6 Phase II trial of weekly paclitaxel with bevacizumab for patients with small cell lung cancer
Track 7 Potential advantages of nab paclitaxel versus paclitaxel
Track 8 Design and results of SWOG-S9504 and SWOG-S0023
Track 9 Hoosier Oncology Phase III trial evaluating docetaxel consolidation for patients with Stage III non-small cell lung cancer (NSCLC)
Track 10 Prophylactic use of growth factor support with lung cancer regimens
Track 11 Importance of maintaining dose intensity in the adjuvant setting
Track 12 Phase II trial combining bevacizumab with chemoradiation therapy for Stage III disease
Track 13 Potential role of adjuvant bevacizumab for NSCLC
Track 14 Mechanism of action and predictors of response to bevacizumab
Track 15 Selection of adjuvant systemic therapy
Track 16 Irinotecan/cisplatin versus etoposide/cisplatin for patients with small cell lung cancer
Track 17 Differences in response to treatment in Japanese populations
 
Edward S Kim, MD
Assistant Professor of Medicine
Director, Educational Programs
Department of Thoracic, Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
  
  Click here to download entire case discussion  
Track 1 Introduction
Track 2 MD Anderson trial of carboplatin/ docetaxel and bevacizumab as first-line therapy for NSCLC
Track 3 Safety and efficacy of different taxanes with bevacizumab
Track 4 Future directions in the management of lung cancer
Track 5 Importance of tissue acquisition in clinical research
Track 6 Case discussion: A 52-year-old woman with NSCLC metastasized to the brain
Track 7 Potential role of predictors of response to select therapy
Track 8 Risk and morbidity associated with tissue acquisition
Track 9 Ongoing trials examining the benefit of cetuximab in the management of NSCLC
Track 10 Potential role of combining biologic agents in NSCLC
Track 11 Efficacy and tolerability of bevacizumab in ECOG-E4599
Track 12 Potential role of bevacizumab in the adjuvant setting
Track 13 Incorporation of biologic agents into the management of Stage III disease
Track 14 Maintenance chemotherapy for patients with Stage III disease
Track 15 Clinical experience with bevacizumab
Track 16 Impact of smoking status on approach to treatment
Track 17 Continuation of bevacizumab after disease progression
Track 18 Impact of cost on the selection of cancer therapies
Track 19 Accrual to clinical trials in lung cancer